Skip to main content
Trending storyContinuously updated

Vitroscope raises $7M for living-tissue drug discovery platform

1 reports1 report sources3 hours agoUpdate

Get up to speed on this story

AI Summary

Vitroscope, a biotech company building perfusion platforms that study immune activity and treatment responses in living human tissue in real time, raised $7 million. The total is a $5 million seed round co-led by Cerberus Ventures and YZR Capital plus $2 million in non-dilutive funding from the Research Council of Norway. The money supports vitro.scale, a system still in development that is designed to run 96 parallel experiments. Vitroscope expects customer testing to begin in 2027, ahead of a planned 2028 launch.

AI-generated from reports · 3 hours agoUpdate

Latest updatesNov 3 18:29
Vitroscope raises $7M to turn living human tissue into drug discovery data

Report timeline

Follow the reports to understand different sides of the story.

Nov 3
  1. Tech.euTop Deals
    Vitroscope raises $7M to turn living human tissue into drug discovery data

    Vitroscope raised $7 million, a $5 million seed round co-led by Cerberus Ventures and YZR Capital plus $2 million in non-dilutive funding from the Research Council of Norway.

Trend for this story

Not enough continuous observation data yet; trend chart is not drawn for now.

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing